Every 10-Q that PURE BIOSCIENCE (PURE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PURE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PURE filings page.
PURE Bioscience, Inc. reports continued losses but modest revenue growth for the three and nine months ended April 30, 2026. Net product sales reached $506,000 for the quarter and $1,656,000 year-to-date, up from $489,000 and $1,435,000 in 2025. Net loss was $624,000 for the quarter and $1,873,000 for nine months, similar to the prior year, as operating expenses remained higher than gross profit.
The company highlights substantial doubt about its ability to continue as a going concern, with a stockholders’ deficiency of $5,839,000 and total convertible notes and accrued interest of $6,497,000. To support liquidity, PURE raised about $1.0 million through a private placement of 18,131,096 common shares at $0.0553 per share and issued $970,000 of new related-party convertible notes. Cash and cash equivalents improved to $983,000, but operations used $1,324,000 of cash over nine months.
The company increased authorized common shares from 200 million to 250 million, with 130,017,569 shares outstanding as of June 15, 2026, and notes that its debt is currently convertible into 57,763,172 shares. PURE also announced a leadership transition: CEO Robert Bartlett will retire effective August 1, 2026, with President Jeffrey Kitchell becoming Chief Executive Officer and joining the Board.
PURE Bioscience, Inc. reported higher sales but continued losses for the three and six months ended January 31, 2026, while warning about its ability to continue as a going concern. Net product sales rose to $443,000 for the quarter and $1,150,000 for the six-month period, reflecting broader demand across its end‑user network.
Despite a six‑month gross margin of 60%, PURE posted a six‑month net loss of $1,249,000, narrowing from $1,487,000 a year earlier, and a quarterly net loss of $785,000. Operating cash outflows were $856,000 for six months, leaving only $198,000 in cash and $273,000 including restricted cash.
PURE’s balance sheet remains highly leveraged and negative. As of January 31, 2026, stockholders’ deficiency was $6,273,000, total assets were $788,000, and total liabilities were $7,061,000, including $6,145,000 of convertible notes and accrued interest owed to related parties. Management and the auditor both cite substantial doubt about the company’s ability to continue as a going concern without new financing.
PURE Bioscience, Inc. reported results for the three months ended October 31, 2025, with modest sales growth but ongoing losses and a weak balance sheet.
Total revenue reached $708,000, up from $556,000 a year earlier, as net product sales rose across its customer base. Gross profit improved to $450,000 and gross margin increased to 64%, helped by higher-value packaging. Operating expenses fell to $829,000, mainly from lower selling, general and administrative costs.
Despite these improvements, PURE recorded a net loss of $464,000 and used $250,000 in operating cash. Cash and cash equivalents were only $434,000 at October 31, 2025, against current liabilities of $3,159,000 and a stockholders’ deficiency of $5,546,000. Management and the independent auditor highlight substantial doubt about the company’s ability to continue as a going concern, noting reliance on related-party convertible notes totaling $5,677,000 that are currently convertible into 46,563,461 shares of common stock.